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Background: Neonatal acute liver failure (NALF) is a rare and life-threatening condition. It causes bilirubin to accumulate 
to a dangerous level in the body, causing permanent damage to vital organs such as the brain and lungs. In many cases, 
the etiology of NALF remains unknown. Case presentation: We described a case of an 8-day-old baby girl who presented 
with poor oral intake, lethargy, and jaundice. Her clinical condition rapidly deteriorated with progression to multi-organ 
failure, and despite intensive resuscitation efforts, she expired. At autopsy, the most significant findings were liver necrosis, 
yellow hyaline membrane deposition in the lungs, and bilirubin deposition in the brain (kernicterus). Conclusions: NALF 
is a rare and potentially fatal condition necessitating prompt recognition and disease-specific treatment approaches. Toxic 
accumulation of bilirubin in the lungs can lead to hypoxia and precipitate further ischemic injury to the liver. 
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INTRODUCTION
Neonatal acute liver failure (NALF) is a rare and 
life-threatening condition.1 It is defined as a multi-
systemic syndrome with liver failure and does not 
require hepatic encephalopathy as a defining feature. 
Over the last decade, with changing diagnostic 
criteria, the treatment approach and outcome have 
significantly evolved. Although these four grouped 
etiologies can account for most cases of NALF: 
Gestational alloimmune liver disease (GALD), viral 
infections, Hemophagocytic lymphohistiocytosis (HLH), 
and mitochondrial hepatopathies; in many cases of 
NALF the etiology is considered “indeterminate.”1,2 
NALF causes significant bilirubinemia, which in turn 
accumulates to dangerous levels and may cause 
permanent damage to vital organs such as the brain 
and lungs. Mortality rates for NALF are still as high as 
24%.1 We discuss the autopsy findings in an 8-day-old 
girl who presented with lethargy, poor oral intake, and 
jaundice with rapid progression to multi-organ failure, 
and review the causes of NALF.
CASE REPORT
An 8-day-old baby girl born at 37 weeks of 
gestation to a previously healthy mother via spontaneous 
vaginal delivery. There were no complications during 
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pregnancy or birth. The patient was brought to the 
hospital with a 2-day history of lethargy, poor oral 
intake and jaundice. Physical examination showed that 
the patient was in respiratory distress. In turn, she was 
placed on continuous positive airway pressure (CPAP) 
and admitted to the neonatal intensive care unit (NICU). 
Laboratory findings on admission revealed significant 
hyperbilirubinemia with a total bilirubin of 31.5 mg/dL 
(RV: 0.2-1.3 mg/dL) and direct bilirubin of 2.4 mg/dL 
(RV: 0.0-0.6 mg/dL). The patient’s condition rapidly 
deteriorated over 24 hours, with worsening lactic 
acidosis and coagulopathy. Electroencephalogram 
(EEG) confirmed seizure activity. An abdominal x-ray 
showed free air in the abdomen, suggesting abdominal 
compartment syndrome. Henceforth, an exploratory 
laparotomy was done; however, no evidence of bowel 
ischemia or perforation was noted. The decision 
was made to leave the abdomen open and to place 
the intestines in a silo bag to assist in resuscitation. 
Work-up for possible sepsis was pursued, and empiric 
treatment with broad-spectrum antibiotics and antiviral 
therapy was initiated. However, the patient’s condition 
continued to deteriorate with refractory hyperkalemia 
(>8 mEq/L), cardioplegia, and cardiogenic shock. Due 
to worsening multi-organ failure, the patient was 
transferred to a tertiary care center on the same day 
for further management.
On arrival to the tertiary care center, the patient 
developed profound hypotension and was placed on 
three vasopressors. Repeat EEG confirmed seizure 
activity and severe encephalopathy. Ultrasound of the 
brain showed increased echogenicity of the bilateral 
basal ganglia. Laboratory findings revealed prolonged 
prothrombin time (PT) of 70.8 seconds (RV: 11-13.5 
seconds), and prolonged partial thromboplastin 
time (PTT) of 117.1 seconds (RV: 30-40 seconds), 
international normalized ratio (INR) of 8.26 (RV: ≤ 1.1), 
serum ferritin > 21,500 ng/mL (RV: 20-200 ng/
mL), lactate dehydrogenase (LDH) of 19,265 IU/L 
(RV: 580-2000 IU/L), total bilirubin of 7.5 mg/dL 
(RV: 0.2-1.3 mg/dL), conjugated bilirubin of 3.3 mg/
dL (RV: 0.0-0.6 mg/dL), unconjugated bilirubin of 
3.9 mg/dL (Reference: 0.5-10.5 mg/dL), alanine 
transaminase of 210 IU/L (RV: 8-32 IU/L), aspartate 
aminotransferase of 1,873 IU/L (RV: 24-72 IU/L), and 
alkaline phosphatase of 270 IU/L (RV: 65-365 IU/L).
Resuscitation attempts for several hours including 
emergent extracorporeal cardiopulmonary resuscitation 
(ECPR)/extracorporeal membrane oxygenation (ECMO) 
without any response and eventually she expired a 
few hours later.
AUTOPSY PRESENTATION
At autopsy, the pertinent significant findings 
included: yellow discoloration of the liver, predominantly 
noted on the right lobe. Microscopic examination 
showed hepatic congestion and geographical ischemic 
necrosis along with intracytoplasmic, canalicular and 
ductular cholestasis (Figure 1). The major bile ducts 
and gallbladder were unremarkable. Prussian stain 
failed to demonstrate any extrahepatic iron deposition. 
Both lungs showed slight yellow discoloration and 
weighed appropriate to age (right: 40 grams, left: 28 
grams) (Figure 2A). Microscopic examination showed 
congestion with extensive deposition of bright yellow 
pigment within the alveolar spaces (Figure 2B). A 
portion of the jejunum and ileum identified within 
a silo bag showed intramural hemorrhage, vascular 
congestion, and focal necrosis consistent with 
bowel infarct. The spleen showed congestion. The 
bone marrow showed trilineage hematopoiesis and 
appropriate cellularity to age. Both kidneys showed 
medullary congestion, necrosis and sloughing of the 
tubular epithelial cells consistent with acute tubular 
necrosis. Post-mortem blood and lung cultures were 
consistent with post-mortem contamination.
The brain was partially liquefied with extensive 
bright yellow bilirubin pigment deposition noted in 
the fresh state (Figure 3A). These pigments were noted 
most prominently in the basal ganglia and thalamus 
(Figure 3B) in addition to scattered portions of the 
brain, including the cerebellum, bilateral occipital 
lobes, and areas around the lumen of the fourth 
ventricle. Microscopic examination demonstrated 
marked distortion of the architecture of the cerebral 
hemispheres with vacuolation, severe gliosis and 
numerous neurons with cytoplasmic eosinophilia and 
nuclear pyknosis, associated with the presence of 
yellow-orange cytoplasmic pigment (Figure 4). The 
most extensive damage was noted in the frontal and 
occipital cortices where there was abundant yellow 
pigment microscopically, diffuse vacuolation associated 
with neurons with cytoplasmic eosinophilia and nuclear 
pyknosis as well as vascular congestion and architectural 
distortion of the gray and white matter. All these 
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findings were consistent with bilirubin encephalopathy 
/ kernicterus. Gross and microscopic examination of 
other organs were unremarkable. Liver polymerase 
chain reaction (PCR) for bacteria, fungus, toxoplasma, 
adenovirus, parvovirus B19, cytomegalovirus, varicella 
zoster virus, herpes simplex virus 1 and 2 was negative. 
Hemophagocytic lymphohistiocytosis (HLH) genetic 
panel was negative.
DISCUSSION
Neonatal acute liver failure (NALF) is a rare and 
poorly understood disease. In adults, acute liver 
failure (ALF) is defined as an international normalized 
ratio (INR) of ≥ 1.5 not corrected with parenteral 
vitamin K, in the presence of hepatic encephalopathy 
occurring within eight weeks of the onset of jaundice 
Figure 1. Microscopic image of liver showing patchy areas of necrosis (H&E; 20x in A and 40x in B).
Figure 2. Yellow hyaline membrane disease. A – Gross image showing bilateral congested lungs with slight yellow 
discoloration; B – Microscopic image showing extensive intra-alveolar bilirubin pigment deposition. (H&E, 40x).
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without pre-existing liver disease.3 However, because 
encephalopathy is difficult to assess or quantify in 
neonates and young children, the Pediatric Acute Liver 
Failure Study Group (PALF) defines it as: an INR ≥2 
without correction with vitamin K, with or without 
encephalopathy in children aged less than 18 years 
old.3 Neonates with ALF show high mortality rates 
approaching as high as 24%.2 The most common 
mechanism leading to ALF among this population is 
acute hepatic necrosis; however, while there are many 
known causes for NALF, in many cases the etiology 
remains indeterminate.2 Taylor and Whitington2 
proposed a simplified differential diagnosis for NALF 
and divided them into four etiologic categories: 
(i) GALD-NH (Gestational alloimmune liver disease - 
neonatal hemochromatosis), (ii) viral infections, (iii) HLH, 
and (iv) mitochondrial hepatopathy. In their experience, 
GALD was the most common cause of NALF, which is 
due to complement-mediated hepatocyte injury due 
to the transfer of maternal IgG across the placenta.2 
GALD is also the most common cause of neonatal 
hemochromatosis (NH), characterized by increased 
iron deposition in extrahepatic tissues such as the 
salivary glands, thyroid, myocardium, and pancreas.4 
Neonates with GALD/NH often present with a history 
of intrauterine growth restriction and signs of liver 
failure, including bleeding, anasarca, and culture 
negative sepsis.2
Viral infections are also considered a common 
cause of NALF, herpes simplex virus (HSV) being the 
most common.2 HSV is acquired by the passage through 
the birth canal of infected mother.2 Rarely, other 
viruses have also been associated with NALF including 
Human Herpesvirus 6 (HHV6), cytomegalovirus (CMV), 
enterovirus and adenovirus.2 Viral infections can be 
detected using polymerase chain reaction (PCR) among 
other methods; PCR was negative in our case.
Figure 3. Kernicterus. A – Gross image of the brain with bilirubin pigment deposition in the fresh state; B – Gross 
image of coronal section of the brain with bilirubin pigment deposition in the basal ganglia, post-fixation.
Figure 4. Microscopic image of the cerebral hemisphere 
showing extensive vacuolation, gliosis, numerous 
neurons with cytoplasmic eosinophilia and nuclear 
pyknosis, associated with yellow-orange cytoplasmic 
pigment deposition (H&E, 40x).
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HLH is another underrepresented cause of NALF.5 
The disease in neonates and infants can be primary 
due to a genetic mutation affecting cytotoxic T-cell 
and Natural Killer-cell function or secondary (due to 
viral infection or neoplasms), resulting in excessive 
immune activation;6 other etiologies of HLH include 
viral infections and neoplasms. Diagnostic criteria 
for HLH include a combination of the following: 
fever, splenomegaly, pancytopenia, hyperferritinemia 
(>20,000 ng/mL), hypertriglyceridemia, decreased 
fibrinogen level, and evidence of hemophagocytosis 
in the bone marrow, spleen, liver, or lymph node.7 
Genetic testing for HLH in our case was negative.
Other causes of NALF that do not show hepatic 
necrosis include mitochondrial and metabolic disorders 
such as: tyrosinemia, galactosemia, and hereditary 
fructose intolerance.1 Hypoxic-ischemic injury is 
sometimes associated with NALF; however, the 
newborn liver is relatively refractory to hypoxic insult.2,6 
Furthermore, other signs of circulatory failure leading 
to hypoxia/tissue ischemia usually precede signs of liver 
injury. Our case disclosed hypoxic ischemic damage to 
the central nervous system.
As a result of acute liver injury, bilirubin level 
increases beyond the capacity of which the newborn 
may process, leading to accumulation and widespread 
deposition in vital organs. Kernicterus is traditionally 
used to describe the pathological yellow staining 
(icterus) of the deep nuclei (“kernel”) of the brain. It is 
a permanent disabling condition usually encountered 
when serum unconjugated bilirubin level exceeds 
25 mg/dL [8]. This condition is characterized by 
extrapyramidal movement disorders such as dystonia 
and choreoathetosis, hearing loss, and oculomotor 
paresis, reflecting the regional central nervous system 
(CNS) topography of bilirubin-induced damage.8
Another prominent finding in our case was the 
extensive yellow pigment deposition in the lungs. The 
deposition of bright yellow pigment in the lungs, termed 
“yellow hyaline membrane disease” (YHMD), was first 
described at the beginning of 1965.9 This observation 
coincides with the initiation of an active intensive care 
unit for premature infants and prolonged survival of 
severe respiratory distress syndrome cases.9 In one 
of the most extensive morphological study on YHMD 
published by Turkel and Mapp10 in 1983, where a total 
of 667 cases with hyaline membrane disease (499 with 
pink, and 168 with yellow membranes) were included, 
it was reported that YHMD was a more frequent 
finding among premature infants who survived longer. 
Grossly, YHMD is characterized by yellow coloration that 
does not fade on exposure to air, light, or prolonged 
refrigeration.11 Microscopically, the yellow hyaline 
membranes (YHMs) are visible as a permanent bright 
yellow pigment which are unaffected by conventional 
hematoxylin and eosin staining. The yellow pigment can 
be seen lining the alveolar space, diffusely within hyaline 
membranes, or freely within the alveolar and bronchiolar 
lumen, or macrophages.11 Valdés-Dapena et al.9 used 
Hall’s stain to identify the presence of yellow bilirubin 
pigment in YHMD. By electron microscopy, the yellow 
membranes consist of needle-like structures varying 
in length from 2.500 Ǻ to 5.000 Ǻ and in width from 
250 Ǻ to 400 Ǻ, interpreted as either bilirubin-protein 
or bilirubin-lipoprotein complexes.9 Using scanning 
spectrophotometer, Morgenstern et al.12 identified that 
the homogenates of lungs with YHMs showed a unique 
absorption shoulder at 454 nm, which corresponded to 
the absorbance of unconjugated bilirubin. Additionally, 
thin layer chromatography of the extracted yellow 
hyaline membrane material produced two unique 
spots similar to those of chemically pure bilirubin.12 
Interestingly, unlike bilirubin deposition in other body 
sites causing icterus and kernicterus, the presence of 
the YHMs does not correlate with the increased peak 
level of serum bilirubin.11 It was believed that mild 
hyperbilirubinemia, in the presence of other factors such 
as hypoproteinemia, and decreased bilirubin binding 
to albumin could result in diffusion through alveolar 
walls damaged by prolonged shock and the deposition 
of unconjugated bilirubin on the previously formed 
intra-alveolar hyaline membranes.10 Another study also 
suggests the role of acute pulmonary hemorrhages in 
the formation of yellow hyaline pigment in the lungs.13
CONCLUSION
In summary, we reported a case of NALF, presenting 
with rapidly progressive multi-organ failure. Significant 
autopsy findings included liver and kidney damage, 
kernicterus and prominent yellow hyaline membrane 
disease. Although two of the leading causes of NALF 
were ruled-out in this case (HLH and viral infection), 
the cause of acute liver failure remains indeterminate 
as the possibility of alloimmune associated hepatitis 
and other rare mitochondrial/metabolic disorders could 
not be ruled out.
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